Vijay K. Ulaganathan

The paper demonstrates antibody-mediated knockdown of intracellular protein expression to target specific protein variants, offering new therapeutic strategies for genotype-specific inhibition of pathogenic variants.

TraPS-VarI identifies human germline receptor variants modulating STAT3 binding sites using variant call format data and checks for associated therapies and clinical trials.

The paper shows cancer cell shed particulates can perform DNA-dependent protein synthesis and are active under specific conditions.